June 8, 2026
ImCheck's ex-CEO on the $1.2B exit to Ibsen, key ASCO oncology trends like ADCs, and critical lessons for biotech founders on fundraising.
June 1, 2026
PathoQuest CEO Jean-François Brepson on scaling a CRO with NGS tech, US expansion, and the strategic acquisition by Charles River.
May 25, 2026
Ex-Incyte CEO Hervé Hoppenot on scaling 10x, navigating biotech cycles, trusting biology over forecasts, and why bureaucracy is a choice.
May 11, 2026
Christoph Lengauer of Curie.Bio discusses their founder-centric VC model, offering deep operational support and higher equity for biotech founders.
April 13, 2026
Forbion's Sander Slootweg on closing Europe's biotech funding gap, pioneering Asian asset in-licensing, and building a resilient VC ecosystem.
April 8, 2026
Immunethep tackles the AMR crisis with a novel vaccine targeting bacterial immune evasion, offering a broad-spectrum solution beyond antibiotics.
February 16, 2026
Novonesis CSO Claus Fuglsang on leading the biosolutions revolution through its $12B merger, a powerful R&D engine, and customer-centricity.
February 9, 2026
Cereno Scientific's CEO on repurposing an old drug for PAH, detailing positive Phase 2a data, a multi-layered IP strategy, and a large retail investor base.
January 12, 2026
Transgene's CEO discusses next-gen cancer vaccines, individualized therapies, and their recent €105M fundraising to advance their platforms.
January 6, 2026
Biotech veteran Pascal Touchon on the cell therapy evolution, from Kymriah to in vivo CAR-T, and JTO's data-driven investment strategy.
![Solving Antimicrobial Resistance, Vaccines, Antibiotics | Immunethep 🇵🇹 | E55 [Sponsored] thumbnail](https://d3t3ozftmdmh3i.cloudfront.net/staging/podcast_uploaded_episode/38602414/38602414-1775472100828-2b361bd18cd64.jpg)
![Sten R. Sörensen, Cereno Scientific 🇸🇪 | Drug Repurposing, Retail Investors | E52 [Sponsored] thumbnail](https://d3t3ozftmdmh3i.cloudfront.net/staging/podcast_uploaded_episode/38602414/38602414-1770668818564-0e3602876c1a2.jpg)
